
Sign up to save your podcasts
Or


A new study from the NIAID revealed that at least 50% of Covid-19 patients treated with a 5-day dosage of Gilead’s Remdesivir reported improved symptoms and were discharged from the hospital within two weeks. Former FDA Commissioner Dr. Scott Gottlieb describes the treatment as “part of a better toolbox” for fighting the coronavirus, but “not a home run.” Plus, Mindy Grossman, CEO of WW International, (formerly known as Weight Watchers) discusses keeping her business and our bodies well during quarantine.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By CNBC4.2
526526 ratings
A new study from the NIAID revealed that at least 50% of Covid-19 patients treated with a 5-day dosage of Gilead’s Remdesivir reported improved symptoms and were discharged from the hospital within two weeks. Former FDA Commissioner Dr. Scott Gottlieb describes the treatment as “part of a better toolbox” for fighting the coronavirus, but “not a home run.” Plus, Mindy Grossman, CEO of WW International, (formerly known as Weight Watchers) discusses keeping her business and our bodies well during quarantine.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

4,085 Listeners

1,355 Listeners

240 Listeners

154 Listeners

521 Listeners

1,170 Listeners

2,201 Listeners

326 Listeners

67 Listeners

154 Listeners

294 Listeners

33 Listeners

45 Listeners

2,149 Listeners

1,302 Listeners

586 Listeners

5 Listeners

20 Listeners

1,561 Listeners

213 Listeners

410 Listeners

300 Listeners

119 Listeners

825 Listeners

171 Listeners

34 Listeners

10 Listeners

29 Listeners

9 Listeners

16 Listeners

2 Listeners